António Gil‐Nagel

9.2k total citations · 3 hit papers
170 papers, 5.0k citations indexed

About

António Gil‐Nagel is a scholar working on Psychiatry and Mental health, Pediatrics, Perinatology and Child Health and Cellular and Molecular Neuroscience. According to data from OpenAlex, António Gil‐Nagel has authored 170 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 127 papers in Psychiatry and Mental health, 70 papers in Pediatrics, Perinatology and Child Health and 47 papers in Cellular and Molecular Neuroscience. Recurrent topics in António Gil‐Nagel's work include Epilepsy research and treatment (125 papers), Pharmacological Effects and Toxicity Studies (60 papers) and Neuroscience and Neuropharmacology Research (44 papers). António Gil‐Nagel is often cited by papers focused on Epilepsy research and treatment (125 papers), Pharmacological Effects and Toxicity Studies (60 papers) and Neuroscience and Neuropharmacology Research (44 papers). António Gil‐Nagel collaborates with scholars based in Spain, United States and United Kingdom. António Gil‐Nagel's co-authors include Rafael Toledano, Irene García‐Morales, Pablo Martínez‐Martín, Lorenzo Morlán Gracia, Jocelyn Gomez, F Bermejo, Ángel Aledo‐Serrano, Stephen S. Rich, Eric W. Johnson and Martin J. Brodie and has published in prestigious journals such as Nature Communications, Journal of Neuroscience and Physiological Reviews.

In The Last Decade

António Gil‐Nagel

160 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Unified Parkinson's disease rating scale characteristics and structure

1994 651 citations António Gil‐Nagel et al. profile →
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome

2020 192 citations Ian Miller, Ingrid E. Scheffer et al. profile →
Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens

2019 180 citations Rima Nabbout, Sameer M. Zuberi et al. profile →

Peers

Countries citing papers authored by António Gil‐Nagel

Since Specialization

Citations

This map shows the geographic impact of António Gil‐Nagel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by António Gil‐Nagel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites António Gil‐Nagel more than expected).

Fields of papers citing papers by António Gil‐Nagel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by António Gil‐Nagel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by António Gil‐Nagel. The network helps show where António Gil‐Nagel may publish in the future.

Co-authorship network of co-authors of António Gil‐Nagel

This figure shows the co-authorship network connecting the top 25 collaborators of António Gil‐Nagel. A scholar is included among the top collaborators of António Gil‐Nagel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with António Gil‐Nagel. António Gil‐Nagel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Human hippocampal reactivation of amygdala encoding-related gamma patterns during aversive memory retrieval 2025 ·Nature Communications ·(unknown), (unknown), António Gil‐Nagel, Rafael Toledano, Lukas Imbach, Johannes Sarnthein, Bryan A. Strange	1
2	A tool for Dravet syndrome-associated neuropsychiatric comorbidities evaluation (DANCE) 2024 ·Epilepsy & Behavior ·Simona Giorgi, Stéphane Auvin, An‐Sofie Schoonjans, Eulalia Turón‐Viñas, (unknown), António Gil‐Nagel, Lieven Lagae, (unknown)	4
3	Comprehensive scoping review of fenfluramine's role in managing generalized tonic–clonic seizures in developmental and epileptic encephalopathies 2024 ·Epilepsia ·António Gil‐Nagel, J. Helen Cross, Orrin Devinsky, Berten Ceulemans, Lieven Lagae, Kelly G. Knupp, An‐Sofie Schoonjans, Philippe Ryvlin, Elizabeth A. Thiele, (unknown), Amélie Lothe, Rima Nabbout	4
4	Use of Stiripentol in Patients with Dravet Syndrome: Common Practice Among Experts in Spain 2024 ·Neurology and Therapy ·Juan José Garcı́a-Peñas, (unknown), (unknown), António Gil‐Nagel, Vicente Villanueva, Rocío Sánchez‐Carpintero	1
5	Patient profile, management, and quality of life associated with Dravet syndrome: a cross-sectional, multicentre study of 80 patients in Spain 2023 ·Scientific Reports ·António Gil‐Nagel, Rocío Sánchez‐Carpintero, Vicente Villanueva	6
6	Cenobamate in patients with highly refractory focal epilepsy: A retrospective real-world study 2023 ·Seizure ·Álvaro Beltrán‐Corbellini, (unknown), (unknown), (unknown), Pablo Iruzubieta, Juan Luis Chico‐García, Paloma Parra‐Díaz, Irene García‐Morales, Rafael Toledano, Ángel Aledo‐Serrano, António Gil‐Nagel	23
7	Epileptogenic focal lesions in Dravet syndrome: A warning to investigators 2023 ·Epileptic Disorders ·(unknown), Álvaro Beltrán‐Corbellini, Rafael Toledano, (unknown), Irene García‐Morales, António Gil‐Nagel	3
8	Interim Analysis of Long-Term Safety and Efficacy of FINTEPLA (fenfluramine) in Patients with Lennox-Gastaut Syndrome (S13.010) 2022 ·Neurology ·Kelly G. Knupp, Ingrid E. Scheffer, Berten Ceulemans, Joseph Sullivan, Katherine Nickels, Lieven Lagae, Renzo Guerrini, Sameer M. Zuberi, Rima Nabbout, Kate Riney, (unknown), Anupam Agarwal, Michael Lock, Gail Farfel, Bradley S. Galer, Arnold R. Gammaitoni, Ronald L. Davis, António Gil‐Nagel	2
9	The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis 2022 ·Epilepsy & Behavior ·António Gil‐Nagel, Mercè Falip, Rocío Sánchez‐Carpintero, (unknown), José Luís Poveda, (unknown), Elena Cardenal‐Muñoz, (unknown), (unknown), (unknown), José Luís Trillo, (unknown), (unknown)	14
10	Fenfluramine significantly reduces day‐to‐day seizure burden by increasing number of seizure‐free days and time between seizures in patients with Dravet syndrome: A time‐to‐event analysis 2021 ·Epilepsia ·Joseph Sullivan, Nicola Specchio, Orrin Devinsky, Stéphane Auvin, Μ. Scott Perry, Adam Strzelczyk, António Gil‐Nagel, David Dai, Bradley S. Galer, Arnold R. Gammaitoni	25
11	Tratamiento de la epilepsia con perampanel: desde la terapia añadida a la conversión a monoterapia 2021 ·Revista de Neurología ·Rafael Toledano, António Gil‐Nagel	1
12	Identifying key unmet needs and value drivers in the treatment of focal-onset seizures (FOS) in patients with drug-resistant epilepsy (DRE) in Spain through Multi-Criteria Decision Analysis (MCDA) 2021 ·Epilepsy & Behavior ·Vicente Villanueva, Mar Carreño, António Gil‐Nagel, Pedro J. Serrano‐Castro, José M. Serratosa, Manuel Toledo, Elena Alvárez‐Barón, (unknown), (unknown)	17
13	Initiating antiepilepsy treatment: An update of expert consensus in Spain 2020 ·Epilepsy & Behavior ·Vicente Villanueva, J C Sánchez-Alvarez, Mar Carreño, Javier Salas‐Puig, (unknown), António Gil‐Nagel	6
14	Antiseizure medication withdrawal in seizure-free patients with PCDH19-related epilepsy: A multinational cohort survey 2020 ·Seizure ·Ángel Aledo‐Serrano, Teodoro del Ser, António Gil‐Nagel	8
15	Cannabidiol (CBD; 10 And 20 MG/KG/Day) Significantly Reduces Convulsive Seizure Frequency In Children And Adolescents With Dravet Syndrome: Results Of A Dose-Ranging, Multi-Center, Randomised, Double-Blind, Placebo-Controlled Trial (GWPCARE2) 2019 ·Epilepsia ·Ian Miller, Ingrid E. Scheffer, Boudewijn Gunning, Rocío Sánchez‐Carpintero, António Gil‐Nagel, (unknown), Russell P. Saneto, Daniel Checketts, (unknown), Eduardo Dunayevich, Volker Knappertz	1
16	The Surgical Approach to the Anterior Nucleus of Thalamus in Patients With Refractory Epilepsy: Experience from the International Multicenter Registry (MORE) 2018 ·Neurosurgery ·Kai Lehtimäki, Volker A. Coenen, A Gonçalves-Ferreira, Paul Boon, Christian E. Elger, Rod S Taylor, Philippe Ryvlin, António Gil‐Nagel, Frans Gielen, Thomas C. Brionne, (unknown), (unknown), (unknown)	48
17	Validez de las escalas clínicas y de contenido del Inventario Multifásico de Personalidad de Minnesota-2 para el diagnóstico de crisis no epilépticas psicógenas 2014 ·Neurología ·(unknown), Adolfo Jiménez‐Huete, Rafael Toledano, Irene García‐Morales, António Gil‐Nagel	1
18	A FAST PATHWAY FOR FEAR 2013 ·UCL Discovery (University College London) ·Constantino Méndez‐Bértolo, Stephan Moratti, Rafael Toledano, António Gil‐Nagel, (unknown), Roberto Martínez‐Álvarez, (unknown), Bryan A. Strange	1
19	Safety and tolerability of different titration rates of retigabine (ezogabine) in patients with partial-onset seizures 2013 ·Epilepsy Research ·Victor Biton, António Gil‐Nagel, Martin J. Brodie, Sarah E. DeRossett, Virinder Nohria	15
20	Early clinical experience with lacosamide as adjunctive therapy in patients with refractory focal epilepsy and nocturnal seizures 2011 ·Seizure ·Irene García‐Morales, Rafael Toledano, Mercè Falip, Dulce Campos, (unknown), António Gil‐Nagel	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact